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Intravascular platelet activation in the hemolytic uremic syndrome. We
studied intravascular platelet activation in patients with typical (epi-
demic) and atypical (sporadic) HUS and found defective aggregation,
decreased platelet and increased plasma serotonin in both groups. The
findings were present not only on admission during the thrombocy-
topenic stage of the disease, but persisted for several weeks after
recovery of the platelet count. Reduced endothelial PG!2 production
was significantly more common in plasma from atypical than typical
cases. Plasma from both typical and atypical HUS patients induced
aggregation of normal platelets, but this phenomenon was unrelated to
both the presence of thrombocytopenia or the stage of the disease.
Serum platelet aggregating activity was higher in the atypical HUS
patients, and was not associated with immune complexes detectable by
polyethylene glycol precipitation. The data indicate that intravascular
platelet activation is a feature of both forms of HUS, and may be
initiated by different mechanisms in the two subgroups. While abnormal
PG!2 synthesis appears to be important in the atypical cases, neither
defective PG!2 production nor platelet aggregation by plasma factors
adequately accounts for platelet activation in the majority of typical
cases.
The hemolytic uremic syndrome (HUS) is one of the more
common causes of acute renal failure in children in developed
countries [1]. Despite its prevalence, its etiology and pathogen-
esis remain poorly understood. Early theories of pathogenesis
invoked activation of coagulation pathways as a prominent
initiating event [2, 3]. However, other studies failed to confirm
disordered coagulation [4—7], and instead have focused on
abnormalities of platelet/endothelial interaction. There is evi-
dence of platelet activation in HUS [5, 6, 8] for which a variety
of mechanisms have been proposed: deficiency of prostacyclin
(PGI2) production [9, 10], circulating platelet aggregating mate-
rial (such as Factor VIII multimers [11]), immune complexes
([12], or bacterial toxins [13, 14]), and platelet contact with
damaged endothelium [15]. Evidence in favor of each of these
hypotheses has been reported, and has prompted trials of a
variety of therapeutic strategies, such as P01, infusion [16, 17],
plasma infusion [18, 19], and plasma exchange [20—22], mostly
with inconclusive results. It may be that much of the contra-
dictory data reported on the pathogenic mechanisms and ther-
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apy is due to the possibility that different processes are involved
in different subgroups of the disorder.
Evidence from clinical [23, 24], epidemiological [23, 25],
pathological [26], and pathophysiological studies [27, 28] sug-
gests that HUS is not a single disease entity, but is a clinical
syndrome resulting from a variety of different disease pro-
cesses. Two principal subgroups have been identified in chil-
dren: typical cases with a diarrheal prodrome occurring in
young children who have a good prognosis; in contrast to
atypical cases with an insidious onset, a tendency to recur-
rence, and a worse prognosis. This latter subgroup is heteroge-
neous. Some cases have a familial occurrence [23], and some
are clinically and pathologically indistinguishable from throm-
botic thrombocytopenic purpura (TTP). Previously we have
referred to the typical and atypical forms as epidemic and
sporadic, respectively [27].
In order to establish whether intravascular platelet activation
is a consistent pathophysiological feature of HUS, at what
stages of the illness it occurs, and whether the mechanisms
causing platelet activation differ in these two main subgroups of
HUS, we have prospectively studied a large group of children
consisting of cases from both subgroups.
Methods
Patients
HUS was diagnosed in 69 children admitted to the Hospital
for Sick Children in London, between 1980 and 1985, who had
microangiopathic hemolytic anemia, thrombocytopenia and re-
nal failure. Patients with septicemia, primary malignant hyper-
tension and vasculitic disorders were excluded. Patients in our
study were classified on the basis of the presence or absence of
a diarrheal prodrome, and their clinical details are summarized
in Table 1.
Typical (epidemic) HUS
Sixty children who presented with HUS following a prodro-
mal diarrheal illness were considered to have typical HUS.
Forty—seven (78%) of them presented in the summer or early
autumn (May to Oct), and many were admitted in close tempo-
ral association with other cases. There were 26 boys and 34 girls
ranging in age from 0.4 to 13.7 years (median 2.5 yr). Fifty—eight
survived, of whom only five (9%) have residual renal dysfunc-
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Table 1. Clinical details
Subgroup
Typical
diarrhea
present
Atypical
diarrhea
absent
Number % total
Male N (%)
Age (yr) median (range)
60 (87%)
26 (43%)
2.5 (0.4—13.7)
9 (13%)
5 (56%)
6.0 (0.1—13.5)
Presentation May—Oct N (%)
Duration of prodrome days
median (range)
47 (78%)
8 (2—14)
1 (1 1%)
10 (0—2 1)
Dialysis N (%)
Duration days median (range)
51 (85%)
9 (0—38)
7 (78%)
3 (0—37)
Outcome
Death N (%)
Relapse N (%)
Persistant renal dysfunction N
(% ofsurvivors)
2 (3%)
0
5 (9%)
2 (22%)
7 (78%)
5 (71%)
a P < 0.01 vs. typical cases; (chi-squared test)
tion (proteinuria, hypertension, or GFR less than 80
mllmin/1.73 m2 S.A. six months or more after onset of the
disease). Two patients died, one from neurological disease, the
other from fulminant colitis. None of them had a family history
of HUS nor experienced recurrent episodes.
Atypical (sporadic) HUS
Nine children who developed HUS without a diarrhea! pro-
drome were considered to have the atypical form of the disease.
In most cases the illness developed insidiously following an
upper respiratory tract infection or vague non-specific symp-
toms. Only one case presented in the months of May to
October. There were 5 boys and 4 girls ranging in age from 0.1
to 13.5 years (median 6.0). Only 2 patients made a full recovery.
The other 7 patients followed a relapsing course, 2 of whom
died of neurological complications during a relapse, and the 5
surviving patients all have residual renal dysfunction. None of
these patients had a family history of HUS.
Methods
Sample collection
Additional quantities of venous blood for the study were
obtained from 56 of the patients at the same time as venepunc-
ture for routine clinical purposes. Informed parental consent
was obtained and the study was approved by the Ethical
Committee of the Hospital for Sick Children. Plasma and serum
were prepared by centrifugation and stored at —70°C until used.
Evidence of platelet activation
Platelet aggregation in vitro (17 patients studied). Platelet
aggregation studies were performed on citrated platelet rich
plasma (PRP) by the standard turbidimetric technique using a
Payton dual channel aggregometer. Studies were performed
within two hours of sample collection and were undertaken only
if the patient's PRP platelet count exceeded 90 X 109/liter. A
normal control was studied simultaneously with each HUS
patient. Response to the following platelet agonists was as-
sessed: adenosine diphosphate (ADP) (2, 4 and 10 smollliter),
adrenaline (2, 4 and 10 smol/liter), collagen (1 sgJml) and
arachidonic acid (1 mmollliter), but, because of limited volumes
of blood available, it was not possible to assess the response to
all of these agents in every case.
Plasma and intraplatelet serotonin (30 patients studied).
Plasma and intraplatelet serotonin were measured in acid citrate
dextrose (ACD) anticoagulated blood using the method of
Parbtani, Frampton and Cameron [29]. After determining the
platelet count, 0.5 ml PRP was added to 0.5 ml EDTA 0.4%
(wtlvol) pH 7.0, and the platelets separated by centrifugation at
2,000 g in an Eppendorf microfuge. The supernatant was saved
and the platelet pellet was resuspended in 1 ml distilled water to
lyse the platelets. The serotonin was measured in the superna-
tant plasma and in the lysed platelets by the method of
Drummond and Gordon [30], and the results expressed as nglml
for the plasma concentration, and as ng/106 platelets for the
intraplatelet content.
Mechanisms of platelet activation
Support of prostacyclin (PGI2) synthesis (42 patients stud-
ied). The ability of patients' citrated plasma to support PG!2
production by normal endothelial tissue was assessed by a
modification of a bioassay described previously [101. The en-
dothelial tissue used was 1 to 2 mm sections of rat aorta
prepared from freshly sacrificed animals, then washed for one
hour in barbitone buffered saline pH 7.4 (BBS). These aortic
rings were incubated for 10 minutes in patient or control
plasma. The supematant from each incubation was tested for
the presence of PG!2 by determining its ability to inhibit
aggregation of normal platelets challenged with ADP in a
concentration just sufficient to cause full aggregation. The
supernatant was added to normal PRP (volume ratio 1:4) and
stirred for one minute in the aggregometer (prior to addition of
ADP) to exclude the presence of potent platelet aggregating
activity in the test plasma. Because it is not possible to
accurately determine the amount of endothelial tissue in a ring,
and because successive incubations of a given ring results in
eventual loss of PG!2 generating ability, quantitative compari-
sons of the amount of PGI2 produced during incubations is
misleading. Therefore, paired cross-over experiments were
performed for each patient's plasma, which enabled compari-
son of the performance of an individual ring during successive
incubations in both patient and control plasma. The order of the
incubations was: (a) BBS; (b) patient's plasma; and (c) control
plasma, with a brief wash in BBS after each stage. The order of
steps (b) and (c) was reversed in the paired experiment using a
second aortic ring. Patients in whose plasma PG!2 production
was less than in control plasma on both occasions were classi-
fied as having reduced support of PG!2 production. All samples
showing reduced support were re-assayed on at least one
occasion.
In an attempt to establish whether failure to support PG!2
synthesis was due to lack of a necessary factor, or due to a
labile inhibitor, some samples which failed to support PG!2
synthesis were re-tested after storage at 4°C for 48 hours, and
other samples were re-tested for support of PGI2 synthesis after
addition of equal volumes of normal plasma.
Aggregation of normal platelets by patient's plasma (32
patients tested). The presence of plasma factors which induce
aggregation of normal platelets was assessed as follows: PRP
was obtained from a normal adult and the count adjusted to 400
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x 109/liter. 200 pA control PRP was then mixed with 200 pA HUS
citrated plasma (volume ratio 1: 1) and stirred in a Payton dual
channel aggregometer at 900 rpm for five minutes. Due to
variability in both the number and the size of platelet aggregates
formed, aggregation was assessed in two different ways: (1)
qualitatively, by microscopic examination of the PRP for the
presence of platelet aggregates: and (2) quantitatively, by the
change in the light transmission through the PRP recorded by
the aggregometer, and expressed as a percentage of the maxi-
mum deflection seen when full aggregation of the donor plate-
lets is produced by ADP.
In an attempt to define the nature of the platelet aggregating
material in HUS plasma, positive samples from 12 cases were
tested after incubation with equal volumes of normal plasma at
37°C for one hour.
Serum platelet aggregating titer (PAT) (34 patients studied).
A modification of the method of Pentinnen and Myllyla was
used to determine the titer at which serum aggregated washed
normal platelets resuspended in phosphate buffer [31, 32].
Serum was prepared from blood collected into a glass tube and
clotted at 37°C for one hour. The results are expressed as the
log2 multiple of the highest titer at which aggregation was
observed in the normal control serum, and a value '2 was
taken to indicate a significantly raised titer.
Immune complexes (17 patients studied). Immune complexes
were studied by precipitation from serum after incubation at
4°C for 48 hours in 2% polyethylene glycol (PEG). The amounts
of IgG, 1gM and Clq in the precipitate were measured by the
Mancini single radial immunodiffusion technique, and the amount
of IgA was measured by the Ouchterlony double diffusion
technique [33].
Results
Evidence of platelet activation
Platelet aggregation in vitro. Platelet aggregation in response
to aggregating agents was reduced in all but one of 17 patients
(8 atypical, 9 typical) studied within 10 days of admission (Fig.
1). The median aggregation, even with high concentrations of
Patients N Platelet ngIlO6 Plasma ng/ml Platelet: plasma
Typical 26 263° (38-1820) 832° (240-2884) 0.3° (0.1-2.0)
Atypical 3 166b (23—1202) 479° (159-1445) 0.3° (0.1—1.6)
Controls 42 447 (224-891) 96 (69-132) 4.7 (2.5-8.9)
ADP (10 mol/liter), was only 40% of control (range 14 to 53%).
Similarly reduced aggregation was seen in response to adrena-
line, collagen, and arachidonic acid. Following complete recov-
ery of the illness, platelet aggregation returned to normal in 13
out of 14 patients studied. However, in patients with relapsing
HUS, platelet response to aggregating agents was again reduced
during subsequent episodes.
Plasma and intraplatelet serotonin. Plasma serotonin con-
centration was increased in all but one of 27 typical patients and
all 3 atypical patients studied within three days of admission
(Table 2). High serotonin concentrations were also found in
these atypical patients during late relapses. Compared to nor-
mal children, both typical and atypical HUS cases had signifi-
cantly higher plasma serotonin concentrations (P < 0.001),
lower intraplatelet serotonin (P < 0.01 for typical, P < 0.02 for
atypical), and lower platelet/plasma serotonin ratios (P < 0.001;
Table 2).
During recovery, the plasma serotonin concentration re-
mained elevated in the typical HUS patients for several weeks
after onset of the illness (Fig. 2). In addition, the plasma
serotonin concentration remained elevated and the platelet!-
plasma ratio decreased even though the platelet count had
returned to normal (Fig. 3). In patients with atypical HUS who
relapsed, plasma serotonin was increased and both intraplatelet
and platelet/plasma serotonin ratio were reduced during each
relapse (Fig. 4).
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Fig. 1. Reduced response to aggregating
agents of both typical (•) and atypical (A)
patients' platelets studied within 10 days of
admission. The aggregation of patients'
platelets 5 mm after addition of the agonist is
expressed as a percentage of that observed in
Collagen Arachidonate control platelets studied at the same time.
,sg/ml mmol/liter Points joined by a line represent observations
made on the same patient.
Table 2. Platelet and plasma serotonin
Serotonin: mean (range)
a p < 0.01
b P < 0.02
° P < 0.001 vs. controls; (i-test)
Means, range (± 2 SD), and t-test on logged data.
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Mechanisms of platelet activation
Support of PGI2 synthesis. The ability of plasma to support
PG!2 synthesis by rat aortic rings was studied within seven days
of admission in 42 patients (33 typical and 9 atypical). Dimin-
ished support of PG!2 synthesis was observed in 7 (77%) of the
atypical but in only 9(27%) of the typical cases (P < 0.01; Table
3). All samples showing reduced support were re-assayed on at
least one occasion, and in all cases the finding was re-con-
firmed. Four of the atypical cases showed decreased support of
Table 3. Platelet aggregating material and support by plasma of PG!2
production
Typical HUS Atypical HUS
Platelet aggregating material in plasma
Number studied 26 6
Present (%) 21(81%) 6 (100%)
Support by plasma of PG!2 production
Number studied 33 9
Decreased (%) 9 (27%) 7 (77%)
PGI2 synthesis during successive relapses. A representative
trace from an HUS plasma with decreased support is shown in
Figure 5. Following recovery the PG!2 support was normal in all
12 patients studied (5 typical, 7 atypical). Storage at 4°C for 48
hours of HUS plasma from 4 patients showing deficient PG!2
support restored the abi'ity to support PG!2 production nor-
mally in one sample, suggesting a labile inhibitor, but had no
effect on the other three. Mixing HUS plasma from 6 patients
showing deficient PG!2 support with an equal volume of normal
plasma resulted in restoration of normal PGI2 support in all the
samples.
Platelet aggregating material. Addition of HUS plasma to
normal platelets repeatedly induced aggregation detected mi-
croscopically in 21 out of 26 typical cases, and in all 6 atypical
cases studied, irrespective of the source of donor platelets
(Table 3). When this aggregating activity was assessed by
aggregometry and expressed as a percentage of maximum
deflection, a range of 0 to 25 (mean 9.3 + 7.0) in typical cases,
and 7 to 11 (mean 9.3 + 2.1) in atypical cases was found. Plasma
samples from the 5 typical cases which did not show micro-
scopic aggregating activity all produced aggregation of less than
7% deflection, but out of the samples from cases which did
show microscopic aggregating activity, one sample produced
only 3.5% aggregation, and six other samples produced only 7%
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show a simultaneous fall in the platelet count and a rise in the plasma
Fig. 2. Plasma serotonin concentrations of typical HUS patients dur- creatinine.
ing recovery. Points joined by a line represent observations made on the
same patient, Elevated concentrations are found for several weeks after
onset of the illness.
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FIg. 3. Relationship between the plasma serotonin concentration and
the whole blood platelet count of typical HUS patients during recovery.
Points joined by a line represent sequential observations made on the
same patient. Elevated plasma concentrations are seen for some time
after the platelet count has returned to normal.
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Fig. 5. Representative trace for an HUS plasma showing reduced support of PG!2 synthesis. After successive 10 mm incubations of 2 different
rat aortic rings in buffer and test plasma, supernatant was added to normal PRP which was then challenged with ADP. Platelet aggregation is
represented by deflection of the trace in the direction shown by the arrow. Following incubation first in buffer, supernatants from neither ring
inhibited platelet aggregation. The rings were next incubated in control plasma or patient's plasma. Only the supernatant from ring I incubated in
control plasma inhibited platelet aggregation, indicating synthesis of PGI2 by that ring, but not by ring 2 incubated in patient's plasma. A cross-over
incubation was next performed, and the supernatant from ring I incubated in patient's plasma now failed to inhibit platelet aggregation, indicating
reduced PGI2 synthesis. Conversly, ring 2 incubated in control plasma now synthesized PGI2.
aggregation. Because of the poor correlation between evalua-
tion by microscopy and aggregometry, and because the magni-
tude of many of these aggregation deflections may fall within
the limits of experimental variability of aggregometry, micro-
scopic examination was considered to be the more reliable
indicator of platelet aggregating activity. On no occasion did
either normal plasma or plasma from 6 children with acute renal
failure due to other causes show microscopic aggregating activ-
ity or produce aggregation of more than 3.5% of maximum
deflection.
The relationship between both the presence and potency of
the aggregating effect of HUS plasma and the platelet count or
stage of the disease was inconsistent. In 6 patients the aggre-
gating activity was not detected by microscopy on admission
when the patients were thrombocytopenic, but was observed
after recovery of the platelet count, and in 3 patients, the
aggregating activity persisted throughout the acute stage of the
disease. Seven patients studied after recovery of the disease no
longer showed platelet aggregating activity. Incubation of 12
positive samples with normal plasma did not abolish the aggre-
gating activity in any.
Serum platelet aggregating titer (PAT). The serum PAT was
raised (2) in 12 out of 26 typical cases (46%), and in 5 out of
8 atypical cases (63%) when studied within three days of
admission (Fig. 6). Values of 3 were observed in significantly
more atypical than typical cases (P < 0.01, chi-squared test).
When studied following recovery, the PAT was normal in 9 out
of 11 patients. When the platelet aggregating activity in plasma
was compared with that in serum on matched samples, the
relationship was inconsistent, with some patients showing
plasma aggregating activity at a time when the serum PAT was
normal, and others having a raised serum PAT when plasma
aggregating activity was not detectable (Table 4).
Immune complexes. Immune complexes of IgG, 1gM, or IgA
sub-classes were not detected, nor was Clq elevated in PEG
precipitates of samples from any of the 17 patients studied, even
though 7 of them had a raised serum PAT.
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Fig. 6. Serum platelet aggregating titer (PAT) of HUS patients studied
within 3 days of admission. Symbols are: (El) typical HUS; atypical
HUS.
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TabLe 4. Platelet aggregating material in plasma, and serum PAT in
matched samples
Serum PATPlasma platelet
aggregating material sI
Present 6 6
Absent 4 3
Discussion
Recent studies of the pathophysiological features of HUS
have revealed a wide variety of phenomena, and have led to
several different mechanisms being proposed to account for the
pathogenesis [34]. It may be that much of the present confusion
is attributable to the heterogeneity of the syndrome, and
different pathogenic mechanisms occur in different patients.
Clinical [23, 24], epidemiological [23, 25], pathological [26], and
pathophysiological studies [27, 28] suggest that at least two
different subgroups can be identified in children; a typical
(epidemic) form, and an atypical (sporadic) form.
Our data indicate that intravascular platelet activation occurs
in patients from both the typical and the atypical subgroups of
childhood HUS during the acute phase of the illness. Their
platelets fail to respond normally to aggregating agents, with a
pattern suggesting platelet degranulation or exhaustion [8].
They are depleted in their granule content with low levels of
intraplatelet serotonin, and plasma levels of serotonin are
increased, This intravascular platelet activation persists after
the platelet count has returned to normal, and may continue for
several weeks in both subgroups. In atypical cases, intravascu-
lar platelet activation may be detected again during successive
relapses, and may be sustained in progressive cases. Our data
thus confirm and extend the observations made by Pareti et al
[35] and Fong and Kaplan [8] who documented circulation of
degranulated platelets in HUS, and those of Edefonti et al [36]
who demonstrated increased plasma levels of platelet derived
factors and reduced intraplatelet serotonin. These findings,
together with the shortened platelet survival [5, 6], and the
megakaryocytic hyperplasia seen in the bone marrow [37]
confirm that intravascular platelet activation is the cause of the
thrombocytopenia in HUS, and suggest that it is not only
present in the acute phase, but persists for some weeks after
onset of the disease.
A number of possible mechanisms have been suggested to
explain the intravascular platelet activation [27]. Early theories
proposed that the platelet and red cell destruction were due to
mechanical damage and entrapment of the cells during passage
through arterioles occluded with fibrin [38, 39]. Intravascular
fibrin formation was suggested by initial studies in HUS [2, 3],
and anticoagulation recomended. However, other studies doc-
umented normal fibrinogen turnover [5, 6], normal or increased
plasma concentration of coagulation factors [4, 7], and a lack of
benefit from anticoagulant [40, 41] or fibrinolytic therapy [42,
43]. In this study, routine coagulation tests revealed significant
intravascular fibrin formation (as suggested by raised fibrin
degradation products, decreased plasma fibrinogen, and pro-
longed prothrombin, partial thromboplastin and thrombin times)
in only 5 (6%) patients (1 atypical and 4 typical cases, data not
shown), whereas, continuing platelet activation was demon-
strated in all patients studied. This suggests that intravascular
fibrin formation is unlikely to be the cause of the platelet
activation.
More recently, disordered interaction between platelets and
the vascular endothelium has been implicated in the pathogen-
esis of HUS. Remuzzi et al reported an HUS patient whose
vascular tissue failed to produce P012 in vitro, and whose
plasma failed to support P012 production by rat endothelial
tissue [9]. He suggested that the pathogenesis was due to lack of
a normal plasma factor required to stimulate P012 synthesis. An
imbalance between the vasodilator and anti-aggregating activity
of P012 and the vasoconstrictor and aggregating action of
thromboxane A2 was an elegant explanation for the platelet
activation in HUS. Diminished synthesis of PGI2 by endothelial
tissue incubated with HUS plasma has been reported by others
[9, 10, 17, 44]. A number of different explanations for this
phenomenon have been suggested, including lack of a normal
factor required for P012 synthesis [9], the presence of inhibitors
[10], and excessively rapid degradation [45].
In a previous study on a smaller number of patients, we found
that reduced P012 synthesis was a feature only of atypical cases
[10]. The present study confirms our previous observation that
support of P012 synthesis is normal in the majority of cases of
typical HUS (73%), and reduced in most cases with the atypical
HUS (77%). However, the distinction is not absolute. Our
attempts to establish whether the abnormality is due to defi-
ciency of a stimulating factor, or presence of an inhibitor have
produced inconclusive results. In one patient whose plasma
showed reduced P012 supporting activity, storage of the plasma
resulted in restoration of normal support, suggesting a labile
inhibitor. Mixing six other patient's plasma showing reduced
support with normal plasma corrected the defect in a pattern
suggesting replacement of a missing factor, rather than neutral-
ization of an inhibitor. Further studies including fractionation of
HUS plasma to identify the inhibiting or stimulating factors are
required to resolve this question.
The finding of abnormal P012 support in only 27% of typical
cases suggests that it is unlikely to be a major factor in the
pathogenesis of most cases of typical HUS. This is supported
by the report by Stuart et al [46] that levels of 6-keto PGF1q (the
main breakdown product of P012) were raised rather than
reduced in cases of typical HUS. The presence of defective
PG!2 support in a minority of typical cases may indicate that the
abnormality is secondary to the HUS process, or that a separate
pathophysiological process is involved in these patients, or that
the clinical subdivision into two groups of patients is imprecise.
Platelet-released /3-thromboglobulin has been shown to inhibit
P012 synthesis [47], and increased levels of /3-thromboglobulin
are known to occur in HUS as a consequence of intravascular
platelet activation [48]. Another mechanism suggested by Stuart et
al whereby the defective P012 support could occur as a second-
ary phenomenon, is consumption of P012 regenerating activity
in an attempt to maintain increased plasma POT2 levels [46].
While defective P012 support seems unlikely to be involved
in the pathogenesis of typical HUS, a role in the pathogenesis of
atypical cases is probable. The presence of this abnormality
during successive relapses and the reports of reduced PG!2
support by plasma from relatives of some affected patients [49,
50] suggest that reduced P012 production may be a primary
abnormality in this group of patients. This theory is perhaps
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supported by the beneficial effects observed in some patients
after fresh plasma infusions [18, 19] or plasma exchange
[20—22].
Abnormal plasma factors have been postulated as the cause
of intravascular platelet activation in both HUS and TTP [51,
52]. A wide number of factors such as abnormal factor Viii
multimers, immune complexes, bacterial products such as
endotoxin and proteolytic enzymes, or complement activation,
could be responsible for platelet activation [11—14]. In atypical
cases and TTP several unusual platelet aggregating factors have
been described.
Lian et a! have investigated a platelet aggregating factor in the
plasma of patients with TTP. This factor induces aggregation of
normal platelets as well as the patient's platelets, and its
activity is inhibited by normal adult plasma or IgG concentrate,
but not by a variety of platelet inhibiting agents [52, 53].
Deficiency of a normal plasma inhibitor of aggregation was
postulated and this inhibitor has subsequently been partially
purified. There is some evidence that the inhibiting factor is an
IgG antibody and that the aggregating factor may be an uniden-
tified infectious agent [54]. Moake et al have implicated abnor-
mally high molecular weight multimers of factor VIII von
Willebrand factor (vWF) as the cause of platelet aggregation in
TTP, and have postulated a primary abnormality of factor VIII
synthesis as the basic defect [55]. Abnormal factor VIII multi-
mers have also been documented in cases of typical epidemic
HUS [11]. Immune complexes of the IgG subclass are also
known to bind to platelets, and have been implicated in abnor-
mal platelet aggregation, especially in TTP associated with
malignancy [56].
We have found that plasma from both typical and atypical
HUS patients induces platelet aggregation. In most cases the
aggregating activity was weak, and was best detected micro-
scopically, only minimal aggregation being detected by ag-
gregometry. However in some cases, the activity was more
potent. There was no consistent relationship between the
presence or potency of this aggregating activity and the stage of
the disease, and patients appeared to improve despite its
persistence. However, following recovery, no patient's plasma
continued to show aggregating activity.
Attempts to establish the nature of the platelet aggregating
material have been unsuccessful. The activity was not removed
by incubation with normal plasma, establishing the material as
distinct from that described by Lian. Immune complexes were
not detected by PEG precipitation. There was a poor correla-
tion between the plasma aggregating activity and the serum
PAT. This was not a surprising finding as these two investiga-
tions differ in principle, and most likely detect different sub-
stances. Plasma platelet aggregating activity is detected when
calcium ions have been depleted by chelation with the citrate
anticoagulant, and relies on aggregation of normal donor,
platelet rich plasma. In contrast the serum PAT is assayed in
the presence of calcium ions, in a system in which coagulation
pathways have been activated during preparation of the serum,
and which relies on agglutination of washed platelets resus-
pended in buffered saline. The lack of correlation between the
plasma platelet aggregating activity and the stage of the disease,
as well as the weakness of the aggregation, suggest that it is
unlikely to be of pathogenic importance, and is perhaps more
likely to be a reflection of widespread cell destruction with
release of cellular constituents into the plasma.
If neither platelet aggregating factors nor defective PGI2
synthesis are responsible for the intravascular platelet activa-
tion in most cases of typical HUS, what then are the mecha-
nisms involved? Recent reports have implicated verotoxin, a
cytotoxin produced by some strains of E. coli, in the pathogen-
esis of HUS [57]. Recently, Levin eta! demonstrated decreased
mitogenic activity in the plasma of typical patients due to an
inhibitor of cell growth which may indicate the presence of a
cytotoxin in these samples [28]. The most prominent histolog-
ical finding in typical HUS is endothelial cell swelling, and
separation of the endothelium from the glomerular basement
membrane [58]. The increased levels of high molecular weight,
factor VIII multimers reported in typical HUS may also be an
indication of endothelial damage. The endothlium is largely
responsible for the nonthrombogenic properties of the vessel
wall, both by the physicochemical properties of its luminal
surface [59], and by the elaboration and localization of platelet
and thrombus inhibiting factors such as PGI2 [60], plasminogen
activator, 2 macroglobulin, histaminase and antithrombin III
[59]. A primary insult to the endothelium, with loss of these
non-thrombogenic properties seems a likely cause of the intra-
vascular platelet activation we have documented, and is an area
which should be investigated in the future.
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